$ALX Oncology (ALXO.US)$ ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma Friday, 25th April at 1:10 pm - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination generate...
$ALX Oncology (ALXO.US)$ ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints Friday, 25th April at 9:00 am In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational study Company remains confident in continuing to pursue evorpacept in multiple c...
$ALX Oncology (ALXO.US)$Reuters· 1 min ago ALX Oncology Receives Ind Clearance From U.S. FDA for Alx2004, a Novel Egfr-Targeted Antibody-Drug Conjugate
$ALX Oncology (ALXO.US)$ ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate Monday, 7th April at 8:00 am • ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology's proprietary linker-payload platform • ALX2004, the company's first ADC, was fully designed and developed in-house by ALX Oncology scientists • Company expects to in...
Trytosaveabit
OP72506401
:
Thats awesome! Im happy but you gotta give yourself credit as well! You decided to trade it! I dont give buy/sell advice! And im very careful with my wording with things like this! And its not that i dont want to. Its because i have NO WAY to know others risk tolerance. Or how they will trade it. And there is also me being wrong! Because, believe me im definitely fallible. Hehehe. Being honest, if i know 100% that a ticker would go up. And knew exactly how much. I would give that to all my followers. Anyways sorry so long a answer to just say CONGRATS on a great trade! Hehehe WTG
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
ALX Oncology Stock Discussion
Breakthrough: New Lymphoma Treatment Achieves 83% Complete Response Rate, Outperforming Standard Therapy
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
Friday, 25th April at 1:10 pm
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity
- Combination generate...
ALX Oncology's Evorpacept Falls Short in Dual Phase 2 Head and Neck Cancer Trials - What's Next?
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
Friday, 25th April at 9:00 am
In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational study
Company remains confident in continuing to pursue evorpacept in multiple c...
ALX Oncology Receives Ind Clearance From U.S. FDA for Alx2004, a Novel Egfr-Targeted Antibody-Drug Conjugate
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
Monday, 7th April at 8:00 am
• ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology's proprietary linker-payload platform
• ALX2004, the company's first ADC, was fully designed and developed in-house by ALX Oncology scientists
• Company expects to in...
No comment yet